Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome

By Elgendy M   Afnan M  

Human Reproduction, Vol. 13, Iss. 9, 1998-09 ,pp. : 2382-2385

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration

By Friedler S.   Raziel A.   Schachter M.   Strassburger D.   Bukovsky I.  

Human Reproduction, Vol. 14, Iss. 8, 1999-08 ,pp. : 1944-1948

Oxford University Press

Access to resources Recommend Favorite

Endocrinology. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization

By Beckers N.G.M.  

Human Reproduction, Vol. 15, Iss. 1, 2000-01 ,pp. : 43-49

Oxford University Press

Access to resources Recommend Favorite

Case report. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization

By de Jong D  

Human Reproduction, Vol. 13, Iss. 3, 1998-03 ,pp. : 573-575

Oxford University Press

Access to resources Recommend Favorite

Endometrial ultrasonography as a predictor of pregnancy in an in-vitro fertilization programme after ovarian stimulation and gonadotrophin-releasing hormone and gonadotrophins

By Oliveira J.B.A.   Baruffi R.L.R.   Mauri A.L.   Petersen C.G.   Borges M.C.   Franco J.G.  

Human Reproduction, Vol. 12, Iss. 11, 1997-11 ,pp. : 2515-2518

Oxford University Press

Access to resources Recommend Favorite